Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Agiolax Micro is a plant-derived combination laxative developed by Madaus GmbH. It consists of psyllium (Plantago ovata) seeds and husks, which act as a bulk-forming agent, and Tinnevelly senna fruits (Senna alexandrina), which serve as a stimulant laxative. The Micro formulation refers to a microgranule presentation of the standard Agiolax product line. It has been investigated under the name Agio-Prep as a bowel preparation agent prior to colonoscopy, where it was compared against standard polyethylene glycol-based preparations like Moviprep in Phase 3 clinical trials. The mechanism involves increasing stool volume and water retention via psyllium while stimulating colonic motility through the action of sennosides on the intestinal mucosa and enteric nervous system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Agiolax Micro.